Management of Common Adverse Events in Patients Treated With Sorafenib: Nurse and Pharmacist Perspective
Open Access
- 1 February 2014
- journal article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 41, S17-S28
- https://doi.org/10.1053/j.seminoncol.2014.01.002
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast CancerJournal of Clinical Oncology, 2012
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation TrialJournal of Clinical Oncology, 2009
- Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974–2002BMC Gastroenterology, 2009
- Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301Journal of Clinical Oncology, 2009
- Phase II Trial of Sorafenib in Metastatic Thyroid CancerJournal of Clinical Oncology, 2009
- Dermatologic symptoms associated with the multikinase inhibitor sorafenibJournal of the American Academy of Dermatology, 2009
- Phase II Trial of Sorafenib in Advanced Thyroid CancerJournal of Clinical Oncology, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaThe New England Journal of Medicine, 2007
- Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control studyArthritis Research & Therapy, 2007